Antithrombotic therapy (i.e., anticoagulants, antiplatelet agents, and fibrinolytics) is used to treat arterial and venous thromboembolic conditions, including acute coronary syndrome, deep venous thrombosis, pulmonary embolism, transient ischemic attack, and ischemic stroke. Moreover, antithrombotic agents help prevent occlusive vascular events in patients at risk for thrombosis due to atherosclerotic arterial disease, atrial fibrillation, medical illness with immobility, or surgical insult. These agents, however, can cause life-threatening complications, primarily serious hemorrhage. Detailed management strategies for thromboembolic disorders are discussed in their respective chapters (see Chapter 47, Acute Coronary Syndromes: Acute Myocardial Infarction and Unstable Angina; Chapter 54, Thromboembolism; and Chapter 161, Stroke, Transient Ischemic Attack, and Cervical Artery Dissection).
Hemostasis—whether physiologic after accidental injury or pathologic after rupture of an atherosclerotic plaque—is initiated by platelet interaction with the vascular subendothelium and continues with a series of reactions among plasma coagulation proteins that generate the final product of cross-linked fibrin incorporated into the initial platelet plug (see Chapter 227, Tests of Hemostasis). Arterial thrombi, composed primarily of platelets bound by thin fibrin strands, develop under high-flow conditions, especially at sites of ruptured plaques. Both anticoagulants and platelet-inhibiting drugs may effectively prevent and treat arterial thrombosis. In contrast, venous thrombi form in areas of sluggish blood flow and are composed mainly of red blood cells and large fibrin strands. Anticoagulant drugs are more effective than antiplatelet drugs in preventing venous thromboembolism.
Antithrombotic agents are classified by their mechanism of action. Anticoagulants block the synthesis or activation of clotting factors, interfering with the coagulation cascade at one or more steps. Antiplatelet agents interfere with platelet activation or aggregation. Fibrinolytic agents (often but inaccurately referred to as thrombolytic agents) stimulate the enzymatic dissolution of the fibrin component.
Oral anticoagulants are used to (1) stop further thrombosis when the condition already exists (e.g., venous thrombosis), (2) reduce the risk of embolism in patients with thrombotic disease (e.g., venous thrombosis or left ventricular mural thrombus), and (3) prevent thrombi from forming in patients with risk factors for their development (e.g., atrial fibrillation, prolonged immobilization, or prosthetic heart valve) (Table 234-1).
Table 234-1 Options for Antithrombotic Therapy |Favorite Table|Download (.pdf)
Table 234-1 Options for Antithrombotic Therapy
|Treatment of Deep Venous Thrombosis and Pulmonary Embolism|
|Unfractionated heparin 80 units/kg IV bolus followed by 18 units/kg per h continuous IV infusion, with the aPTT checked after 6 h and the infusion adjusted to maintain the aPTT 1.5–2.5 times control with concurrent institution of warfarin|
In most cases, heparin and warfarin are started simultaneously, with an overlap of 3–5 d.
Warfarin is monitored and dose adjusted to a target INR of 2.0–3.0 in most patients.
|Enoxaparin 1 milligram/kg SC every 12 h or 1.5 milligrams/kg SC once a day||Monitoring not routinely required|
|Fondaparinux weight-tiered regimen||Monitoring not routinely required|
|<50 kg: 5 milligrams SC once a day||—|
|50–100 kg: 7.5 milligrams SC once a ...|
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.